Combo therapy shows promise in KRAS mutations
Scientists have discovered that dual therapy with drugs already in use for other diseases is effective in cancer caused by the KRAS gene mutation.
So far, they have conducted studies that show the drugs double the survival rate of mice with lung cancer and halt cancer in pancreatic cells.
About 30% of non-small cell lung cancers contain the mutation, which can also lead to cancer in the pancreas, thyroid and colon.
"There really have been no effective treatments to target the KRAS mutation so far," says Dr Inder Verma of the Salk institute and